#119433
Re: Farmas USA
REGN
- Regeneron Pharmaceuticals (REGN +4.9%) Q4 results: Revenues: $2,169.5M (+12.5%); Net product sales: $1,286.4M (+17.3%); Sanofi collaboration revenue: $427.1M (-0.1%); Bayer collaboration revenue: $320.8M (+6.4%).
- Eylea sales in U.S.: $1,222.1M (+13.3%); Libtayo global sales: $74.7M.
- Dupixent global net sales: $751.5M (+135.7%); Praluent: $81.4M (-15.4%); Kevzara: $59.7M (+69.6%).
- Net Income: $792M (-3.5%); EPS: $6.93 (-3.1%); non-GAAP Net Income: $857.6M (+9.2%); non-GAAP EPS: $7.50 (+9.6%).
«Después de nada, o después de todo/ supe que todo no era más que nada.»